Overall verdict
Neutral
4.4/10
1-year performance
-27.86%
Score breakdown
Down 27.9% over 1 year, 26% of the 52-week range.
Strongest: Growth 8.7/10. Weakest: Shareholder return 0.0/10.
7 analysts, target +1.1% vs the price.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis ;
REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors ; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma ; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies ; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Najat Khan
Founded
2013
Employees
600
Revenue / employee
124 468 USD
Next earnings
February 24, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.23%
- FMR LLC1.84%
- Bank of New York Mellon Corp0.26%
- Rest of the register95.67%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
5.24 USD
52-week low
2.77 USD
1-year performance
-27.86%
Declining
Year-to-date performance
-18.35%
Declining
Drawdown
-35.02%
Major drawdown
Position in the 52-week range
26% of range
Gross margin -40.0%, the company loses 697.1% of its revenue, ROIC -46.1%, ROE -48.7%.
Net margin
-697.13%
Negative
Sector -13.47%|S&P 13.40%
Gross margin
-39.97%
Negative
Return on equity (ROE)
-48.72%
Negative
Sector -17.71%|S&P 17.06%
Return on invested capital (ROIC)
-46.06%
Negative
Free cash flow margin (FCF)
-457.97%
Negative
Margin stability
771.7 pts
Very uneven
Revenue to net income
Growth
8.7/10Revenue up 258.5% over 1 year, 79.9% a year over 5.
Revenue (trailing 12 months)
68.2M USD
Revenue growth (1y)
258.49%
Hyper-growth
Revenue growth (3y)
87.44%
Strong
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 17.4x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
2.1Md USD
Financial strength
6.9/10Cash covers 745.0% of the debt, net debt/EBITDA 1.3x.
Net debt / EBITDA
1.3x
Solid
Gearing (net debt / equity)
-53.19%
Net cash
Cash
557M USD
Cash / market cap
26.22%
Very solid
Cash / total debt
744.99%
Net cash
Interest coverage
-541.6x
Stretched
Net debt
-482M USD
Equity
906M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 3.55 USD
- MM203.79
- MM503.78
- MM2003.49
- RSI 1445.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.19%
200-day average slope, 3 months
-7.90%
50-day average slope, 1 month
+5.67%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
6.54 % per day
Volatility change
+33.94%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.89 (6) | -0.88 (8) | 40 (7) | -426 (4) | -479 (5) |
| 2027 | -0.85 (6) | -0.83 (7) | 44 (8) | -394 (4) | -494 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 4, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 3 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 4 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 5 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 6 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 7 | RXRX | 4.4 | 2.8 | 2.1Md USD | Not meaningful (loss) | -697.1 % | 258.5 % | -46.1 % | 1.3x | -14.7 % | -27.9 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
